2018 First Quarter results presentation

Operating income, growth figures, profitability and how our products have behaved.


No votes yet
 
Related
Operating revenue was 151.2 million euros in the first quarter of 2024, a 25% decrease on the first quarter of 2023, mainly due...
4 min
08/05/2024
Agreement to manufacture pre-filled syringes for a global pharmaceutical company Production will take place on one state-of-the-art...
3 min
25/04/2024
Madrid – 2 April, 2024 – Today, Laboratorios Farmacéuticos Rovi, S.A. (“ROVI” or the “Company”) has announced that the U.S. Food and Drug...
4 min
02/04/2024